share_log

Enanta Pharmaceuticals Presenting Preclinical Data for Its Respiratory Syncytial Virus (RSV) and Human Metapneumovirus (HMPV) Programs at the 12th International RSV Symposium

Enanta Pharmaceuticals Presenting Preclinical Data for Its Respiratory Syncytial Virus (RSV) and Human Metapneumovirus (HMPV) Programs at the 12th International RSV Symposium

Enanta制药公司在第12届呼吸道合胞病毒(RSV)国际研讨会上介绍其呼吸道合胞病毒(RSV)和人类偏肺病毒(HMPV)计划的临床前数据
Benzinga Real-time News ·  2022/09/29 07:12
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced new preclinical data related to its RSV program, as well as new virology methods used for its RSV and hMPV programs, will be presented during the 12th International RSV Symposium at ICC Belfast in Northern Ireland, United Kingdom. An oral presentation and poster highlight the preclinical characteristics and the in vivo efficacy of EDP-323, a novel non-nucleoside RSV L-inhibitor. Additional posters characterize a 3D culture model for studying RSV, as well as outline methods for improved...
亚洲网加利福尼亚州圣何塞10月24日电埃南塔制药公司(纳斯达克市场代码:ENTA)是一家致力于开发治疗病毒感染和肝病的小分子药物的临床阶段生物技术公司。该公司今天宣布,与其呼吸道合胞病毒计划相关的新的...
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发